Abivax ADR(ABVX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -6.1 | Insider Own | 9.41% | Shs Outstand | 79.8M | Perf Week | -1.13% |
| Market Cap | 7.57B | Forward P/E | - | EPS next Y | 5.33% | Insider Trans | - | Shs Float | 79.3M | Perf Month | -5.01% |
| Enterprise Value | 7.11B | PEG | - | EPS next Q | -0.92 | Inst Own | 55.94% | Short Float | 9.81% | Perf Quarter | -30.37% |
| Income | -0.47B | P/S | - | EPS this Y | 24.76% | Inst Trans | 10.62% | Short Ratio | 6.88 | Perf Half Y | -22.7% |
| Sales | 0.00B | P/B | 16.49 | EPS next 5Y | 34.25% | ROA | -139.89% | Short Interest | 7.78M | Perf YTD | -35.86% |
| Book/sh | 5.25 | P/C | 16.46 | EPS past 3/5Y | -17.73% -12.77% | ROE | -258.43% | 52W High | -41.88% ($148.83) | Perf Year | -4.69% |
| Cash/sh | 5.25 | P/FCF | - | Sales past 3/5Y | - | ROIC | -111.69% | 52W Low | 23.91% ($69.81) | Perf 3Y | 855.8% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -101.86% | Gross Margin | - | Volatility(W/M) | 4.44% 4.31% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 4.22 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.97 | EPS Q/Q | -98.18% | Profit Margin | - | RSI (14) | 38.36 | Recom | 1.28 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.97 | Sales Q/Q | - | SMA20 | -4.4% ($90.48) | Beta | 1.38 | Target Price | $157.26 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/9/21 | SMA50 | -15.74% ($102.66) | Rel Volume | 0.38 | Prev Close | $88.01 |
| Employees | 69 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -24.6% ($114.72) | Avg Volume(3M) | 1.13M | Price | $86.5 |
| IPO | 2023/10/20 | Option/Short | Yes/Yes | Trades | 5878 | Volume | 423,721 | Change | -1.72% |
A US-listed American Depositary Receipt (ADR) of a clinical-stage biotech company developing treatments for chronic inflammatory diseases. The company is developing its oral drug candidate, obefazimod—which modulates immune response—for ulcerative colitis. This is a drug development stock whose share price is largely driven by clinical trial results and regulatory approval progress.
Over the past 1 year, on the lower side
42% below its 1-year high.
Traded less than usual. That is 38% of its average volume.
ABVX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +24.8% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 3 years ago, your return today would be +855.8%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 55.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #35 of 594 in the industry
Based on market cap of $8B.
FAQ
What kind of company is ABVX?
ABVX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ABVX?
The market cap of ABVX is approximately $7.6B, ranking 1,068 within its sector.
What is the 52-week high and low for ABVX?
ABVX has recorded a 52-week high of $148.83 and a low of $69.81.
